Research Foundation for Mental Hygiene
Research Foundation for Mental Hygiene sponsors 27 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 21 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Posttraumatic Stress Disorder, with 1 trials.
Trial Pipeline
27 total, page 1 of 1
Reducing Self-Stigma Among Individuals with History of Childhood Maltreatment: a Cross-Cultural Lens
NCT06159075
Digital Mental Health Care for COVID-19 High-Risk Populations - Phase 2
NCT05826132
Reducing Self-Stigma Among Individuals with History of Childhood Maltreatment
NCT05818228
Transcendental Meditation in Veterans and First Responders With PTSD
NCT05645042
Digital Mental Health Care for COVID-19 High-Risk Populations
NCT04964570
Acceptance and Mindfulness Based Exposure Therapy for Survivors of Cardiac Arrest
NCT04596891
Reducing Stigma Towards Depression Among Adolescents
NCT04760223
The COVID-19 and Healthcare Workers: An Active Intervention
NCT04497415
Addressing COVID-19 Mental Health Problems Among US Veterans
NCT04484207
Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19
NCT04386291
Targeting Non-virally Suppressed Adults With Alcohol Use Disorder in HIV Primary Care
NCT04280068
Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
NCT03891667
Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression
NCT03765138
Trauma-Focused Equine-Assisted Therapy (TF-EAT) for Veterans With PTSD
NCT03068325
Meditation and Stretching for Post Treatment Lyme Disease Syndrome
NCT02344537
HealthCall-S: A Pilot Study Targeting Concurrent Non-injection Drug Use and Alcohol in HIV Primary Care Clinics
NCT02294318
Attention-Bias Modification Treatment for PTSD
NCT01888653
Armodafinil for Patients Starting Hepatitis C Virus Treatment
NCT01470651
HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics
NCT01312181
Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
NCT01216891
fMRI Predictors of Treatment Response in Posttraumatic Stress Disorder (PTSD)
NCT01576510
Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
NCT01178671
Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS
NCT01158443
A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis
NCT00591318
Reducing Unsafe Alcohol Use in HIV-Positive Individuals
NCT00371969
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
NCT00488163
Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack
NCT01130103
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
| Phase 4 | 5 |
Therapeutic Areas
What the Pipeline for Research Foundation for Mental Hygiene Shows
According to the ClinicalTrials.gov registry, Research Foundation for Mental Hygiene is linked to 27 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 21 are already marked complete, representing roughly 78% of the total.
The phase mix for Research Foundation for Mental Hygiene reports 6 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Research Foundation for Mental Hygiene is Posttraumatic Stress Disorder with 1 linked trial, and 2 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.